We work with whistleblowers to expose fraud against the government.

Best Price Violations

Pharmacy or pharmaceutical company not providing Medicare with best price on drugs.

Often drug companies violate the False Claims Act when they fail to give the government the manufacturer’s “best price” on medications, that is, the lowest price paid by any private commercial customer. For example, the Medicaid Drug Rebate Program requires name-brand drug manufacturers to specify the “best price” given to private commercial customers.

Drug makers pay rebates to state Medicaid programs anytime the government has paid more for medications than the “best price.” The practice works to guarantee that Medicaid programs are offered the same deep discounts enjoyed by large commercial customers. When pharmaceutical companies neglect to reveal the lowest price for their products, they violate the False Claims Act.

Best price violations result in significant damages

Best price violations can result in very significant damages to the government in overpayments, and some major pharmaceutical companies have been involved in False Claims Act lawsuits because of such violations.

Examples of best price violations include the following:

  • In 2009, the U.S. and several states filed False Claims Act suits against Wyeth, alleging that the drug maker intentionally overcharged the government by hundreds of millions of dollars for Protonix Oral and Protonix IV prescribed under state Medicaid programs that ensure health insurance for the poor.
  • Under the Medicaid Drug Rebate Program, name-brand drug manufacturers are required to reveal the “best price” offered to private customers. If the state Medicaid program paid more than this “best price,” the manufacturers are then required to pay rebates to the state Medicaid programs so that the government pays no more for drugs than the best price given to large commercial customers.
  • From 2000 to 2006, Wyeth had arranged with hospitals to offer large discounts when Protonix Oral and Protonix IV were purchased together. Facilities that put both medications on their drug lists and that met or exceeded required market-share goals were given prices reduced 80 and 90% from the list price.
  • The suits against Wyeth allege that the company failed to determine the effective “best price” paid by hospitals and that the deeply discounted prices were not offered to state Medicaid programs. By not calculating and revealing the best price given to hospitals for this drug combination, Wyeth escaped making enormous quarterly rebates to state Medicaid programs.
  • Also in 2009, Aventis Pharmaceutical Inc. paid a substantial amount after admitting that it violated the False Claims Act by over-billing federal and state health programs for medications administered to indigent patients. As part of the Medicaid Drug Rebate Program, Aventis had an obligation to report the lowest price paid for its drugs by large commercial customers and to make rebates to state Medicaid programs based on that price.
  • Rather than meet its obligations under the Medicaid Drug Rebate Program, Aventis intentionally misrepresented its lowest prices, underpaid rebates owed to the states, and over-billed a number of other public health agencies. The medications at issue included Nasacort, Nasacort AQ, and Azmacort, which are all steroidal anti-inflammatory nasal sprays. Aventis’ fraudulent conduct continued from 1995 to 2000.
  • In 2008, Boehringer Ingelheim Roxane Inc., the Ohio pharmaceutical giant, settled False Claims Act litigation in Boston federal court by consenting to pay a sizable amount to resolve charges that the company falsely inflated drug prices reported to nationwide price reporting services.
  • This price inflation to national price reporting services — engaged in by a number of drug makers — caused a substantial overcharge to the Massachusetts Medicaid program (and private medical insurance plans) because the state’s Medicaid system uses the prices published by nationwide drug-price reporting services to establish the amount the Massachusetts program will pay to pharmacies as reimbursement for medications prescribed to state Medicaid patients.

Medicaid Drug Rebate Program is a huge financial incentive

Because of the Medicaid Drug Rebate Program, pharmaceutical companies have a huge financial incentive to hide the best price they give to commercial customers. Concealing this information is a violation of the False Claims Act, however, and costs taxpayers billions of dollars.

What is Qui Tam?

Under the Federal False Claims Act (FCA), whistleblowers have the power to save taxpayers billions of dollars each year by taking a stand against fraud. The U.S. False Claims Act allows private citizens to file suits on the government’s behalf when the government has been defrauded through any federally funded contract or program. The qui tam provisions of the False Claims Act allow these citizens to recover damages. A number of states and the city of Chicago also have laws similar to the False Claims Act to protect against fraud. To learn more about the different types of fraud … READ MORE

New Documentary Finds Roundup “Everywhere”

January 18, 2023 Brian Lilla, an award-winning filmmaker, moved to the Napa Valley wine region to raise his children in a healthy environment. But as he saw Roundup applied vigorously to the vineyards spread throughout the area, he “learned how toxic wine country…

Waters & Kraus founders named to 2022 Texas Super Lawyers list

December 1, 2022 Waters & Kraus LLP is proud to announce that law firm partners C. Andrew Waters and Peter A. Kraus once again have been named to the 2022 Texas Super Lawyers list. The prestigious list recognizes both Waters and Kraus as among the top 5% of Texas attorneys in their practice areas for personal Injury litigation and product liability litigation on behalf of plaintiffs. About Super Lawyers® Super Lawyers is a Thomson Reuters rating publication that annually conducts a rigorous review process to name outstanding lawyers in more than 70 practice areas. The selection process involves peer input and third-party validation…

What are my chances?

That’s the first question everyone asks. The truth is it’s impossible to know. But we can tell you this. Waters Kraus & Paul has what it takes to fight against big corporate interests and win. That’s why we’ve taken more mesothelioma trials to verdict than any other firm. And that’s why we’ve recovered more than $1.3 billion for clients like you. Do you think you have a case? Contact us now to speak with an attorney.

Call 800.226.9880